The safety and immunogenicity of an acellular pertussis vaccine containing the genetically
detoxified pertussis toxin PT-9K/129C, filamentous hemagglutinin, and pertactin, together …

An acellular pertussis vaccine (DTaP) containing pertussis toxoid, filamentous
hemagglutinin and the 69-kDa outer membrane protein (pertactin) was compared with …

An acellular pertussis vaccine principally containing two purified pertussis antigens,
filamentous hemagglutinin and lymphocytosis-promoting factor, combined with diphtheria …

This is the report on a prospective, single blind, comparative study of a component acellular
pertussis vaccine produced by a combination of detoxified, column purified pertussis toxin …

Objectives: The primary objective was to assess the nature and incidence of adverse events
after a fourth dose of a tricomponent acellular pertussis-diphtheria-tetanus vaccine given in …

To determine whether a nontoxic derivative of pertussis toxin obiained by recombinant DNA
technology, PT-9K/129G, is a good candidate for a new pertussis vaccine, we examined the …

This review was stimulated in part by three articles that presented a view of acellular
pertussis vaccine development," which we believe is not supported by the clinical and …

A second generation acellular pertussis vaccine (component pertussis vaccine) containing
purified pertussis toxin (PT) and filamentous hemagglutinin (FHA) was tested for its …

Diphtheria-tetanus-acellular pertussis vaccines have been licensed in the United States
since 1991. Compared with the whole cell pertussis component diphtheria-tetanus-pertussis …

Objective. To compare the immunogenicity and reactogenicity of a diphtheria and tetanus
toxoids and three-component acellular pertussis vaccine (DTaP) with a diphtheria and …